The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Share News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Mind Gym revenue recovers; Dispersion buys Accru

Mon, 18th Oct 2021 15:12

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

Mind Gym PLC - London-based training and management development company - Expects revenue of GBP24.1 million in the six months ended September 30, up 66% year-on-year from GBP14.5 million. Revenue remained slightly above the GBP23.9 million reported in the comparative pre-Covid period, two years earlier. Says 82% of income was "digitally enabled". Continues to invest in its technological capacities ahead of the planned launches of its new digital products. Expects to release its interim results on December 3.

----------

Dispersion Holdings PLC - decentralised finance investor using blockchain and cryptocurrencies to remove financial intermediaries from transactions - Acquires Accru Finance Ltd for GBP8.8 million, to be paid via the issue of 250 million new company shares. Accru's sellers will then hold a 29% stake in Dispersion. The company says Accru plans to launch: "the first internationally-regulated and insured platform for the trading and yield farming of cryptocurrencies." Expects to approve the deal at the company's general meeting next Tuesday.

----------

IXICO PLC- AI data analytics company based in London - Reports revenue of GBP9.2 million in the year ended September 30, down 3.2% from GBP9.5 million a year prior but 5.7% above market expectations of GBP8.7 million. Expects earnings before interest, tax, depreciation and amortisation of GBP1.2 million, in line with market expectations but slightly below the GBP1.3 million taken a year earlier. Notes that this reflects the GBP7.1 million adverse impact of lost revenue from the end of its Huntington's Disease trial in March. Expects lower profitability in financial 2022 as the company invests in long-term sustained growth.

----------

7digital Group PLC - London-based music licensing provider - Secures GBP1 million expansion to revolving credit facility with Investec Bank. Brings total facility with Investec up to GBP2 million total. Says the enlarged facility matures in September 2023, in keeping with the original terms agreed with the bank in September 2020. Issues 5.4 million warrants with an excise price of 0.55 pence and a lifespan of 36 months, as an arrangement fee to Investec.

----------

Artisanal Spirits Co PLC - Edinburgh, Scotland-based owner of the Scotch Malt Whisky Society - Signs 10-year lease for a new supply chain facility in Uddingston, Scotland. Says the 37,000 square foot facility will provide the company with greater control over its supply chain, in order to improve its margins over time. It includes warehousing, production and office space, with equipment due to be installed in early 2022. The facility is scheduled to become fully operation in the second half of 2022, the company adds.

----------

Destiny Pharma PLC - Brighton, England-based clinical stage biotechnology company focused on life threatening infections - Says US hospital-based study supports potential of XF-73 nasal product to reduce intensive care unit infections. The phase 4 study includes 300,000 patients and shows 23% of all ICU infections are caused by the staphylococcus aureus bacteria. Proposes its XF-73 product as an alternative to mupirocin for these infections. Notes current regulatory talks concerning phase 3 studies to obtain marketing approval for XF-73 in the US and Europe.

----------

ReNeuron Group PLC - Bridgend, Wales-based exosome therapeutics company - Sees first subject treated at Oxford Eye Hospital in a Phase 2a RP trial of its therapeutic candidate for retinitis pigmentosa, a degenerative eye disease. The study uses 2 million cell doses on subjects with some remaining vision, despite having advanced retinitis pigmentosa. Appoints Catherine Isted as chief financial officer and executive director. Notes the departure of non-executive director Chris Evans as he approaches non-independent status after nine years on the board.

----------

Hemogenyx Pharmaceuticals PLC - London-based developer of drugs for blood diseases - Leases custom laboratory at the Mink Building in New York from The Janus Property Co. Says the new laboratory is close to Columbia University and City College, possibly easing future collaboration. The 10,000 square foot laboratory includes two purpose built clean rooms. The company says the new space will be used to pursue commercialisation of its major cell therapy product candidates by manufacturing cells in-house, starting with its HEMO-CAR-T treatment for acute myeloid leukemia.

----------

Corcel PLC - London-based mineral explorer and developer with interests in battery metals and flexible energy generation & storage - Acquires Wo Wo Gap Nickel-Cobalt project in Papua New Guinea. Says it acquired the project as it reached a share purchase agreement with Resource Mining Corp Ltd to acquire the entire issued share capital of the project's owner Niugini Nickel Pty Ltd. "Near term priorities at Wo Wo gap will include resource updates, exploring synergies with our Mambare project, and the early securing of long term shipping and offtake arrangements," says Corcel's executive chair James Parsons.

----------

IGas Energy PLC - Lincoln-based oil and gas producer - Agrees head of terms with Iona Capital Ltd to develop utility scale solar farms in the UK. Initially plans to develop a 25 to 40 megawatt solar farm in southern England, the first of several similar projects. "IGas will contribute its planning and infrastructure expertise, whilst Iona will provide non-recourse project finance. During the development phase, costs will be shared and throughout the project lifecycle, IGas and Iona will each own 50% of the project," the company says.

----------

Gem Diamonds Ltd - London-based miner - Recovers high quality Type 2, 245 carat Type 2 and 102 carat white diamonds. Says it uncovered the stones from the Letseng mine in Lesotho, "the highest dollar per carat kimberlite diamond mine in the world".

----------

Ethernity Networks Ltd - Networking and security solutions provider based in Israel - Secures USD3 million order with Chinese broadband network OEM. Says the order is for customised FPGA system-on-chip processors and covers 2022 and 2023. Expecs further orders thereafter. Under the terms of the agreement, the company will supply OEM with its system-on-chip devices with support for four Gigabit Passive Optical Networking Optical Line Termination ports and four 10Gbps XGS-PON OLT MAC ports by the second quarter of 2022. These products support OEM's 5G and fibre access developments.

----------

Castillo Copper Ltd - Australia and Zambia-focused base metal copper exploration company - Begins drilling at its Arya Copper Prospect in the Mount Isa region of Queensland, Australia. Says drilling follows a significant logistical effort to prepare the drill-pads, heli-lift and other equipment at the site. Plans to drill five initial holes as "proof of concept" at the Arya site and expects to expand the campaign to fully test the area. Focuses drilling on targets identified by BHP in the 1990s, including EG01, EG02 and EG101,2. Notes large a potential 130 metre-thick sulphide bedrock conductor at the EG01 target. Says initial observations are encouraging. Notes concurrent rock chip sampling campaign to extend the known surface anomaly to the south.

----------

React Group PLC - South Derbyshire, England-based cleaning, hygiene and decontamination firm - Wins GBP230,000 contract to provide specialist deep cleaning services for a rail sector client. The contract runs for 25-weeks through to the end of March 2022, the company adds. "Securing this contract highlights the quality and depth of work being provided by the specialist teams within the group and continues to strengthen our presence in the rail sector," says Chief Executive Shaun Doak.

----------

Home REIT PLC - London-based real estate investment trust - Spends GBP166.4 million on property pipeline. Acquires 23 portfolios including 366 properties across England and Wales. Funds the purchases with proceeds from its oversubscribed GBP350 million equity issue in September. Says its total property pipeline totals GBP400 million.

----------

By Scarlett Butler; scarlettbutler@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
9 Apr 2019 10:55

ReNeuron Signs Licence Deal For CTX, hRPC Cell Programmes In China

LONDON (Alliance News) - ReNeuron Group PLC on Tuesday said it has signed an exclusive licence agreement for the development, manufacture and commercialisation of its CTX and hRPC cell therapy in

Read more
4 Apr 2019 14:19

ReNeuron upbeat on progress in hRPC study

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group updated the market on progress with its ongoing phase 1 and 2 clinical trial in the US of its 'hRPC' cell therapy candidate in the blindness-causing disease retinitis pigmentosa (RP) on Thursday, confirming that the positive efficacy seen and previously announced had, to date, been sustained in the first patient cohort in the phase 2 part of the study.

Read more
4 Apr 2019 10:32

ReNeuron Shares Rise On Positive Data From Blindness Treatment Trial

LONDON (Alliance News) - Shares rose in ReNeuron Group PLC on Thursday after it reported positive efficacy in a phase one/two clinical trial of its hRPC cell therapy candidate for treating in the

Read more
18 Mar 2019 11:42

ReNeuron Group Starts Dosing Of Second Cohort In hRPC Study

LONDON (Alliance News) - ReNeuron Group PLC on Monday said it started dosing of the second cohort of patients in a phase II study of its hRPC cell therapy candidate in the blindness-causing of in

Read more
18 Mar 2019 11:33

ReNeuron Group begins dosing second cohort in hRPC study

(Sharecast News) - Cell-based therapeutics company ReNeuron Group updated the market on progress with the ongoing phase 1 and 2 clinical trial in the US of its 'hRPC' cell therapy candidate in the blindness-causing disease, retinitis pigmentosa (RP).

Read more
20 Feb 2019 09:47

ReNeuron Reports Positive Preliminary Data In US Retinal Trial

LONDON (Alliance News) - ReNeuron Group PLC on Wednesday reported "significant improvement in vision" in the trial of its hRPC cell therapy candidate for retinal disease.ReNeuron

Read more
20 Feb 2019 08:21

ReNeuron storms on 'exciting' eye disease trial success

(Sharecast News) - ReNeuron Group bounded upward on Wednesday after reporting that its cell-based therapy is showing signs that it can improve the sight of patients suffering from retinitis pigmentosa, which causes blindness.

Read more
31 Jan 2019 09:55

ReNeuron upbeat on data around ease of exosome manufacture

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced on Thursday that new data relating to the manufacturing scale-up of its GMP produced, CTX-derived exosomes was being presented at a US forum on the manufacture of cell and gene therapies.

Read more
24 Jan 2019 12:16

ReNeuron Group Reports First Enrolled Patient In Stroke Clinical Trial

LONDON (Alliance News) - ReNeuron Group PLC on Thursday said it enrolled the first patient in its US Phase IIb clinical study of CTX stem cell therapy for stroke disability.The study is a 6

Read more
24 Jan 2019 09:46

First patient dosed in latest ReNeuron study of CTX cell therapy

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced on Thursday that the first patient has been treated in the US Phase IIb clinical study of its 'CTX' cell therapy candidate for stroke disability.

Read more
4 Jan 2019 07:59

ReNeuron Group to collaborate with unnamed US biopharmaceutical firm

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group has signed a collaboration agreement with an unnamed US-based biopharmaceutical company to explore the use of its exosome technology platform as a potential delivery vehicle for synthetic oligonucleotides used in gene therapy, it announced on Friday.

Read more
14 Dec 2018 12:07

ReNeuron narrows losses as development programmes continue

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group issued its interim results for the six months ended 30 September on Friday, reporting a reduced loss for the period of £5.32m, from £9.57m year-on-year.

Read more
7 Dec 2018 16:01

UK Earnings, Trading Statements Calendar - Next 7 Days

Monday 10 December Photo-Me InternationalHalf Year ResultsHollywood Bowl GroupFull Year

Read more
18 Oct 2018 12:42

Reneuron's stem cell technology could produce cancer-combating cells

(Sharecast News) - New data from a study by Reneuron has encouraged the company that its stem cell technology could be adapted to specifically attack cancerous cells.

Read more
18 Oct 2018 10:54

ReNeuron Reports New Positive Data Relating To CTX Stem Cell Platform

LONDON (Alliance News) - ReNeuron Group PLC on Thursday said its CTX stem cell therapy candidate can be successfully re-programmed to a pluripotent state.Pluripotent state is an embryonic a

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.